

Resource Summary Report

Generated by [RRID](#) on Jul 28, 2026

CD38-FITC, human

RRID:AB_615091

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-092-259, RRID:AB_615091

Antibody Information

URL: http://antibodyregistry.org/AB_615091

Proper Citation: Miltenyi Biotec Cat# 130-092-259, RRID:AB_615091

Target Antigen: CD38

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 2021; Target Distribution B cells, basophils, bone marrow, brain, kidney, leukocytes, lymphocytes, monocytes, myeloid cells, NK cells, ovary, pancreas, placenta, plasma cells, red blood cells, skeletal muscle, T cells, thymocytes; target type CD markers; tested applications MACS Flow Cytometry; quantity: Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-426. (RRID:AB_2733640).

Antibody Name: CD38-FITC, human

Description: This monoclonal targets CD38

Target Organism: human

Clone ID: IB6

Antibody ID: AB_615091

Vendor: Miltenyi Biotec

Catalog Number: 130-092-259

Record Creation Time: 20250820T050751+0000

Record Last Update: 20250820T205221+0000

Ratings and Alerts

No rating or validation information has been found for CD38-FITC, human.

Warning: Discontinued: 2021

Discontinued: 2021; Target Distribution B cells, basophils, bone marrow, brain, kidney, leukocytes, lymphocytes, monocytes, myeloid cells, NK cells, ovary, pancreas, placenta, plasma cells, red blood cells, skeletal muscle, T cells, thymocytes; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-426. (RRID:AB_2733640).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Ascani A, et al. (2023) The role of B cells in immune cell activation in polycystic ovary syndrome. eLife, 12.

Zhong W, et al. (2019) ORP4L Extracts and Presents PIP2 from Plasma Membrane for PLC γ 3 Catalysis: Targeting It Eradicates Leukemia Stem Cells. Cell reports, 26(8), 2166.